$HEXAGON 📊 Q1 FY26 Financial Snapshot Net Profit: ₹807M vs ₹645M (YoY +25%). Revenue: ₹1B vs ₹728M (YoY +38%). EBITDA: ₹117M vs ₹100M (YoY +17%). EBITDA Margin: 11.24% vs 13.83% (YoY decline due to cost pressures). 📌 Fundamentals & Ratios Debt-to-Equity: ~0.3, low leverage and strong balance sheet. P/E Ratio: ~22–24, reflecting growth expectations in the nutrition sector. ROE: ~13–14%, healthy return on equity. EBITDA Margin: 11.24%, slightly compressed YoY. Dividend Yield: ~0.8%, modest shareholder payout. 🥗 Key Projects & Business Drivers Micronutrient Fortification: Expanding fortified foods and supplements. Clinical Nutrition: Growth in medical-grade nutrition products. Exports: Expanding footprint in Asia and Africa. R&D: Focus on innovative formulations in health and wellness. Strategic Partnerships: Collaborations with healthcare providers and NGOs. ⚠️ Risks & Watchpoints Margin Pressure: Rising raw material and input costs. Regulatory Risks: Compliance with food safety and health regulations. Global Demand Cyclicality: Dependent on consumer health trends. Competition: Intense rivalry in nutrition and supplements. Execution Risks: Scaling up new product lines efficiently

#FundamentalViews#StockInNews#Miscellaneous#MacroViews#PersonalFinance

796 likes·46 comments